BUDGET IMPACT ANALYSIS OF INTRODUCING SUBCUTANEOUS INFLIXIMAB CT-P13 SC FROM THE UK PAYER PERSPECTIVE

被引：1
|
作者：
Perry, M. [1 ]
Jang, M. [2 ]
机构：
[1] Royal Alexandra Hosp, Paisley, Renfrew, Scotland
[2] Celltr Healthcare Co Ltd, Incheon, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.3422
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1185
引用
收藏
页码：1879 / 1879
页数：1
相关论文
共 50 条
  • [1] Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
    Byun, Han Geul
    Jang, Minyoung
    Yoo, Hyun Kyeong
    Potter, James
    Kwon, Taek Sang
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (05) : 735 - 745
  • [2] Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
    Han Geul Byun
    Minyoung Jang
    Hyun Kyeong Yoo
    James Potter
    Taek Sang Kwon
    [J]. Applied Health Economics and Health Policy, 2021, 19 : 735 - 745
  • [3] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF SUBCUTANEOUS INFLIXIMAB IN FRANCE FROM A PAYER PERSPECTIVE
    Pradie, M.
    Hadjadj, C.
    Moreau, Petiteau F.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S81 - S81
  • [4] Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU
    Matt Shirley
    [J]. Clinical Drug Investigation, 2021, 41 : 1099 - 1107
  • [5] Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU
    Shirley, Matt
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (12) : 1099 - 1107
  • [6] CT-P13 subcutaneous infliximab in gastroenterology and rheumatology
    Ahmed, Mai
    Bankov, Giulia
    Casey, Dan
    Perry, Martin Edward
    [J]. IMMUNOTHERAPY, 2021, 13 (12) : 1001 - 1009
  • [7] 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn's Disease in UK, Italy and France
    Kim, J.
    Hong, J. An
    Kudrin, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S144 - S145
  • [8] Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
    Hyun Kyeong Yoo
    Han Geul Byun
    Flavio Caprioli
    Mathurin Fumery
    Laurent Peyrin-Biroulet
    Subramanian Sreedhar
    James Potter
    Minyoung Jang
    [J]. BMC Health Services Research, 22
  • [9] Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
    Yoo, Hyun Kyeong
    Byun, Han Geul
    Caprioli, Flavio
    Fumery, Mathurin
    Peyrin-Biroulet, Laurent
    Sreedhar, Subramanian
    Potter, James
    Jang, Minyoung
    [J]. BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [10] SWITCHING FROM ORIGINATOR INFLIXIMAB TO CT-P13: A UK SINGLE CENTRE EXPERIENCE
    Bhandare, Anirudh Pramod
    Crooks, Benjamin
    Nigam, Gaurav Bhaskar
    Limdi, Jimmy K.
    [J]. GUT, 2019, 68 : A70 - A70
12345